Novo Nordisk Inc Drug Patent Portfolio

Novo Nordisk Inc's Family Patents


Family Patents



Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Novo Nordisk Inc News

FDA Greenlights New High-Dose Wegovy in the US for Enhanced Weight Loss - Science Alert

20 Mar, 2026

Novo's High Dose Wegovy Receives Fourth Approval from FDA's National Priority Voucher Program

19 Mar, 2026

FDA Greenlights Enhanced Dosage of Wegovy Injections

19 Mar, 2026

US FDA grants approval for an increased dosage of Novo's Wegovy through a new expedited review process.

19 Mar, 2026

See More